Boehringer to get Zantac rights as part of J&J-Pfizer deal

10/12/2006 | Yahoo!

Johnson & Johnson and Pfizer say they will sell U.S. marketing rights for the heartburn drug Zantac to Boehringer Ingelheim Pharmaceuticals for $509.5 million as part of J&J's planned acquisition of Pfizer's consumer health business. The sale is intended to facilitate Federal Trade Commission approval of the $16.6 billion J&J-Pfizer deal.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Chicago, IL
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC